[go: up one dir, main page]

UY33409A - Moduladores no competitivos de receptores nicotinicos - Google Patents

Moduladores no competitivos de receptores nicotinicos

Info

Publication number
UY33409A
UY33409A UY0001033409A UY33409A UY33409A UY 33409 A UY33409 A UY 33409A UY 0001033409 A UY0001033409 A UY 0001033409A UY 33409 A UY33409 A UY 33409A UY 33409 A UY33409 A UY 33409A
Authority
UY
Uruguay
Prior art keywords
nicotinic receptors
competitive modulators
competitive
methods
modulators
Prior art date
Application number
UY0001033409A
Other languages
English (en)
Inventor
Srinivasa Rao Akireddy
Balwinder Singh Bhatti
Jon-Paul Strachan
Xiao Yunde
Speake Jason
Original Assignee
Targacept Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Targacept Inc filed Critical Targacept Inc
Publication of UY33409A publication Critical patent/UY33409A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/33—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C211/34—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of a saturated carbon skeleton
    • C07C211/38—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of a saturated carbon skeleton containing condensed ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/33—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C211/39—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton
    • C07C211/41—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton containing condensed ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/06—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with radicals, containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/02—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements
    • C07D295/027—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring
    • C07D295/033—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring with the ring nitrogen atoms directly attached to carbocyclic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Addiction (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La presente invención se relaciona con compuestos que modulan receptores nicotínicos como antagonistas no competitivos, con métodos para su síntesis, con métodos para su uso y con sus composiciones farmacéuticas .
UY0001033409A 2010-05-27 2011-05-26 Moduladores no competitivos de receptores nicotinicos UY33409A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34902710P 2010-05-27 2010-05-27
US37560610P 2010-08-20 2010-08-20

Publications (1)

Publication Number Publication Date
UY33409A true UY33409A (es) 2013-01-03

Family

ID=44462072

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001033409A UY33409A (es) 2010-05-27 2011-05-26 Moduladores no competitivos de receptores nicotinicos

Country Status (23)

Country Link
US (6) US8809397B2 (es)
EP (1) EP2576496B1 (es)
JP (2) JP5893610B2 (es)
KR (1) KR101856046B1 (es)
CN (2) CN102918021B (es)
AU (1) AU2011258553B2 (es)
BR (1) BR112012030004A2 (es)
CA (1) CA2799203C (es)
CL (1) CL2012003274A1 (es)
CO (1) CO6680603A2 (es)
ES (1) ES2623373T3 (es)
IL (2) IL223060A (es)
MX (1) MX337106B (es)
NZ (1) NZ603966A (es)
PE (1) PE20130775A1 (es)
PH (1) PH12012502300A1 (es)
PL (1) PL2576496T3 (es)
RU (2) RU2582339C2 (es)
SG (1) SG185643A1 (es)
TW (1) TW201200129A (es)
UY (1) UY33409A (es)
WO (2) WO2011149859A1 (es)
ZA (1) ZA201208836B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2576496T3 (pl) * 2010-05-27 2017-08-31 Catalyst Biosciences, Inc. Niekompetycyjni antagoniści receptorów nikotynowych
EP2773609A4 (en) * 2011-11-03 2015-06-24 Targacept Inc NON-COMPETITIVE MODULATORS OF THE NICOTINE RECEPTOR
WO2013142162A1 (en) * 2012-03-23 2013-09-26 Targacept, Inc. Method of treating bladder disorders
WO2022140677A1 (en) * 2020-12-23 2022-06-30 The Broad Institute, Inc. Compositions and methods related to di-substituted bicyclo[2.2.1] heptanamine-containing compounds

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2931805A (en) * 1958-11-10 1960-04-05 Smith Kline French Lab Spiro [bicyclo [2. 2. 1] heptane-2, 2'-alkylenimines]
US3290215A (en) * 1963-10-29 1966-12-06 Du Pont Use of methanoindanamines as antiviral agents
US3317387A (en) * 1964-05-25 1967-05-02 Du Pont Method of reducing the severity of influenza virus infections
IL107184A (en) 1992-10-09 1997-08-14 Abbott Lab Heterocyclic ether compounds that enhance cognitive function
US5852041A (en) 1993-04-07 1998-12-22 Sibia Neurosciences, Inc. Substituted pyridines useful as modulators of acethylcholine receptors
US5493026A (en) 1993-10-25 1996-02-20 Organix, Inc. Substituted 2-carboxyalkyl-3-(fluorophenyl)-8-(3-halopropen-2-yl) nortropanes and their use as imaging for agents for neurodegenerative disorders
US5597919A (en) 1995-01-06 1997-01-28 Dull; Gary M. Pyrimidinyl or Pyridinyl alkenyl amine compounds
US5604231A (en) 1995-01-06 1997-02-18 Smith; Carr J. Pharmaceutical compositions for prevention and treatment of ulcerative colitis
US5585388A (en) 1995-04-07 1996-12-17 Sibia Neurosciences, Inc. Substituted pyridines useful as modulators of acetylcholine receptors
US5583140A (en) 1995-05-17 1996-12-10 Bencherif; Merouane Pharmaceutical compositions for the treatment of central nervous system disorders
IL118279A (en) 1995-06-07 2006-10-05 Abbott Lab Compounds 3 - Pyridyloxy (or Thio) Alkyl Heterocyclic Pharmaceutical Compositions Containing Them and Their Uses for Preparing Drugs to Control Synaptic Chemical Transmission
JP2802486B2 (ja) 1995-11-30 1998-09-24 花王株式会社 トリシクロカルボン酸エステルおよびその製造法
US5726189A (en) 1996-05-03 1998-03-10 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Method for imaging nicotinic acetylcholinergic receptors in the brain using radiolabeled pyridyl-7-azabicyclo 2.2.1!heptanes
CN2284883Y (zh) 1996-07-12 1998-06-24 陈智 纯滚活齿传动
US6294585B1 (en) * 1996-09-18 2001-09-25 Applied Genetics Incorporated Dermatics Treatment of neurodegenerative diseases
ZA9711092B (en) 1996-12-11 1999-07-22 Smithkline Beecham Corp Novel compounds.
US6310043B1 (en) 1998-08-07 2001-10-30 Governors Of The University Of Alberta Treatment of bacterial infections
GB9821503D0 (en) 1998-10-02 1998-11-25 Novartis Ag Organic compounds
ATE406797T1 (de) * 1998-12-16 2008-09-15 Univ South Florida Exo-s-mecamylamin-formulierung
TW200306189A (en) * 2002-03-21 2003-11-16 Merz Pharma Gmbh & Co Kgaa Azabicyclic, azatricyclic and azaspirocyclic derivatives of aminocyclohexane NMDA, 5HT3, and neuronal nicotinic receptor antagonists
CN1325500C (zh) * 2002-04-18 2007-07-11 阿斯特拉曾尼卡有限公司 呋喃基化合物
US7135575B2 (en) * 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
US7825147B2 (en) * 2003-08-29 2010-11-02 Ranbaxy Laboratories Limited Inhibitors of phosphodiesterase type-IV
WO2005060947A2 (en) * 2003-12-19 2005-07-07 Sri International Agonist and antagonist ligands of the nociceptin receptor
JP2007515478A (ja) * 2003-12-22 2007-06-14 アストラゼネカ・アクチエボラーグ ニコチン性アセチルコリンレセプターリガンド
EP1784184A2 (en) 2004-08-20 2007-05-16 Targacept, Inc. The use of n-aryl diazaspiracyclic compounds in the treatment of addiction
AR054816A1 (es) 2005-07-13 2007-07-18 Banyu Pharma Co Ltd Derivados de n-dihidroxialquil 2-oxo- imidazol sustituidos
TW200845977A (en) * 2007-03-30 2008-12-01 Targacept Inc Sub-type selective azabicycloalkane derivatives
WO2009039181A2 (en) * 2007-09-17 2009-03-26 State Of Oregon Acting By & Through The State Board Of Higher Education On Behalf Of Or. State Univ. Sulfonamide-based organocatalysts and method for their use
US20110071180A1 (en) 2008-03-05 2011-03-24 Targacept, Inc. Sub-type selective amides of diazabicycloalkanes
PL2576496T3 (pl) * 2010-05-27 2017-08-31 Catalyst Biosciences, Inc. Niekompetycyjni antagoniści receptorów nikotynowych
WO2013026852A2 (en) * 2011-08-22 2013-02-28 The Provost, Fellows, Foundation Scholars, And The Other Members Of Board, Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth, Near Dublin Derivatives of mecamylamine

Also Published As

Publication number Publication date
MX337106B (es) 2016-02-12
IL241743A0 (en) 2015-11-30
CL2012003274A1 (es) 2013-05-24
US20190254991A1 (en) 2019-08-22
IL223060A (en) 2015-10-29
RU2012157224A (ru) 2014-07-10
IL223060A0 (en) 2013-02-03
JP5893610B2 (ja) 2016-03-23
CA2799203C (en) 2018-05-08
JP2013528178A (ja) 2013-07-08
EP2576496B1 (en) 2017-03-08
KR101856046B1 (ko) 2018-06-25
NZ603966A (en) 2015-03-27
MX2012013618A (es) 2013-02-01
TW201200129A (en) 2012-01-01
PH12012502300A1 (en) 2013-02-04
BR112012030004A2 (pt) 2016-08-02
US20130203860A1 (en) 2013-08-08
US20170071878A1 (en) 2017-03-16
PE20130775A1 (es) 2013-07-21
CN104557568B (zh) 2017-04-12
US8809397B2 (en) 2014-08-19
US10716770B2 (en) 2020-07-21
AU2011258553B2 (en) 2014-08-14
ZA201208836B (en) 2013-07-31
JP2016172717A (ja) 2016-09-29
WO2011149862A1 (en) 2011-12-01
AU2011258553A1 (en) 2013-01-10
RU2016111390A (ru) 2017-10-04
SG185643A1 (en) 2012-12-28
CN102918021B (zh) 2015-02-11
KR20130075748A (ko) 2013-07-05
RU2582339C2 (ru) 2016-04-27
US10258582B2 (en) 2019-04-16
CN102918021A (zh) 2013-02-06
US20160008323A1 (en) 2016-01-14
WO2011149859A1 (en) 2011-12-01
US20140315877A1 (en) 2014-10-23
US20180271806A1 (en) 2018-09-27
US9532974B2 (en) 2017-01-03
CO6680603A2 (es) 2013-05-31
PL2576496T3 (pl) 2017-08-31
CN104557568A (zh) 2015-04-29
ES2623373T3 (es) 2017-07-11
CA2799203A1 (en) 2011-12-01
EP2576496A1 (en) 2013-04-10

Similar Documents

Publication Publication Date Title
JOP20180103A1 (ar) مركب صيدلاني
UA109931C2 (xx) Піримідинциклогексильні модулятори глюкокортикоїдних рецепторів
CO7151485A2 (es) Anticuerpos anti-sez6 y métodos de empleo
GT201300196A (es) Moduladores del receptor de glucagón
MX2015012456A (es) Compuestos heterociclicos y usos de los mismos.
CO7111274A2 (es) Moduladores dll3 y métodos de empleo
CR20130671A (es) Antagonistas de trpv4
GT201600085A (es) Composiciones y métodos para modular los receptores x farnesoides
UY35500A (es) Indazoles sustituidos con heteroarilo
CR20140106A (es) Compuestos y composiciones como inhibidores de la quinasa c-kit
NI201500077A (es) Novedosos derivados de bencimidazol como antagonistas de ep4
MX2016006725A (es) Moduladores de receptores de glucocorticoides de azadecalina octahidro fusionada.
ECSP11011347A (es) Nicotinamida sustituida como moduladores KCNQ2/3
CR20150549A (es) Compuestos heterocíclicos y sus usos
ECSP13012519A (es) Compuestos sustituidos de benzamida
UY33917A (es) ?composiciones para recubrimiento que comprenden submicropartículas que comprenden carbonato de calcio, proceso para prepararlas, y uso de las submicropartículas?.
MA34075B1 (fr) Composition pharmaceutique comprenant un dérivé pyrimidineone
MX356400B (es) Moduladores novedosos y metodos de uso.
UY34636A (es) Composiciones tópicas que comprenden fipronilo y permetrina y sus métodos de uso
CR20150247A (es) Anticuerpos de antihemaglutinina y métodos de uso
CL2015000976A1 (es) Compuestos de 2-fenil-5-heterociclil-tetrahidro-2h-piran-3-amina para uso en el tratamiento de diabetes y sus trastornos asociados.
GT201400090A (es) 2-tiopirimidinonas
CL2013000733A1 (es) Compuestos derivados de arilalquilimidazol, moduladores selectivos de receptores alfa 2 adrenergicos; y composicion farmaceutica que los comprende.
EA201490519A1 (ru) Селективные модуляторы рецепторов андрогенов
CO7151478A2 (es) Formulaciones estabilizadas que contienen anticuerpos anti-dll4